Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2021-11-16 Regulatory Filings
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Biotest AG: Cytotect CP(R) Biotest activates immune cells that are crucial to control Cytomegalovirus
Regulatory Filings Classification · 95% confidence The document is titled 'News Details' and begins with a 'PRESS RELEASE' announcing study results regarding the product Cytotect CP(R) Biotest and its effect on Cytomegalovirus (CMV). It includes contact information for Investor Relations (IR) and PR, is dated, and is disseminated via DGAP, which handles 'Regulatory Announcements, Financial/Corporate News and Press Releases'. This format strongly suggests a general corporate announcement or press release regarding scientific/product developments, rather than a formal regulatory filing like a 10-K, an Earnings Release (ER), or a specific financial report (IR, AR). Since it is a news announcement about a study result and product information, and it doesn't fit the specific categories like ER, AR, or CT, the most appropriate general category for corporate news dissemination that isn't a formal financial report is Regulatory Filings (RNS), which serves as a broad category for miscellaneous corporate announcements distributed via regulatory channels (like DGAP). It is not a Report Publication Announcement (RPA) because it is the content itself, not just an announcement that a report is attached.
2021-11-16 English
Biotest AG: Biotest increases sales by 9% in the first nine months 2021
Earnings Release Classification · 100% confidence The document is titled 'Biotest increases sales by 9% in the first nine months 2021' and explicitly mentions 'Quarter Results' and provides key financial figures (revenues, EBIT, EAT) for the first nine months of the financial year 2021. This content structure—a press release summarizing period results without being the full, detailed statutory report—aligns perfectly with the definition of an Earnings Release (ER). Although it references the '2021 nine month report' at the end, the document itself is the initial announcement of those results, not the full report itself (which would likely be classified as IR if comprehensive). Since it focuses on period results highlights, ER is the most appropriate classification. 9M 2021
2021-11-11 English
Earnings Release 2021
Earnings Release Classification · 99% confidence The document is titled "Biotest AG Nine Month 2021 Results Conference call" and contains detailed financial tables for Q1-Q3 2021, including Income Statement, Sales development, EBIT reconciliation, and Balance Sheet data. It also includes extensive updates on R&D pipeline projects (IgG Next Generation, Fibrinogen, Trimodulin) and strategic information regarding the Grifols takeover offer. The structure, content (financial performance review, operational highlights, forward-looking statements), and explicit mention of 'Nine Month 2021 Results' strongly indicate this is a comprehensive report covering an interim period, likely presented during an investor/analyst call. This aligns best with the definition of an Interim / Quarterly Report (IR), although the format suggests it might be the presentation slides accompanying an Earnings Release (ER) or Management Discussion & Analysis (MDA). Given the depth of financial tables and operational detail, it surpasses a simple ER and is more comprehensive than a typical MDA, fitting the scope of an IR, which covers comprehensive financial reporting for a period shorter than a year. Since it is a presentation/document detailing the results, and not just a transcript (CT) or a short announcement (RPA/ER), IR is the most appropriate classification for detailed interim financial results. 9M 2021
2021-11-11 English
Investor Presentation 2021
Investor Presentation Classification · 99% confidence The document is titled "Biotest AG Nine Month 2021 Results Conference call" and contains detailed financial tables for Q1-Q3 2021, including Income Statement, Sales development, EBIT reconciliation, and Balance Sheet data. It also includes extensive updates on R&D pipeline projects (IgG Next Generation, Fibrinogen, Trimodulin) and strategic information regarding the Grifols takeover offer. The structure, content (financial performance review, operational highlights, forward-looking statements), and explicit mention of 'Nine Month 2021 Results' strongly indicate this is a comprehensive report covering an interim period, likely presented during an investor/analyst call. This aligns best with the definition of an Interim / Quarterly Report (IR), although the format suggests it might be the presentation slides accompanying an Earnings Release (ER) or Management Discussion & Analysis (MDA). Given the depth of financial tables and operational detail, it surpasses a simple ER and is more comprehensive than a typical MDA, fitting the scope of an IR, which covers comprehensive financial reporting for a period shorter than a year. Since it is a presentation/document detailing the results, and not just a transcript (CT) or a short announcement (RPA/ER), IR is the most appropriate classification for detailed interim financial results.
2021-11-11 English
Q3 statement / Q3 financial report 2021
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Statement' covering the period from 1 January to 30 September 2021. It contains detailed financial performance data, including consolidated statements of income, financial position, and cash flow, as well as management's analysis of business performance, segment results, and financial position. It is a comprehensive interim report rather than a mere announcement or summary, fitting the definition of an Interim/Quarterly Report (IR). 9M 2021
2021-11-11 English
Biotest AG: Joint reasoned statement of Biotest AG - Management Board and Supervisory Board recommend to accept takeover offer of GRIFOLS, S.A.
M&A Activity Classification · 100% confidence The document is a press release titled "Joint reasoned statement of Biotest AG – Management Board and Supervisory Board recommend to accept takeover offer of GRIFOLS, S.A.". It explicitly references the German Securities Acquisition and Takeover Act (WpÜG) and discusses the recommendation regarding a takeover offer. This content directly relates to a proposed merger or takeover bid, which aligns with the definition of M&A Activity (TAR). Although it is a statement about the offer, the core subject matter is the transaction itself, making TAR more specific than a general Regulatory Filing (RNS) or Report Publication Announcement (RPA), especially given the document length (5686 chars) suggests it is the substantive statement, not just a notification of publication.
2021-11-05 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.